Role of activin A and myostatin in human cancer cachexia

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 5, 2015, Pages 2030-2038

  Loumaye, Audrey ^a,b   De Barsy, Marie ^b   Nachit, Maxime ^a   Lause, Pascale ^a   Frateur, Lena ^b   Van Maanen, Aline ^b   Trefois, Pierre ^b   Gruson, Damien ^a,b   Thissen, Jean Paul ^a,b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; MYOSTATIN; ACTIVIN; MSTN PROTEIN, HUMAN;

ADULT; AGED; ANOREXIA; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; CACHEXIA; CANCER STAGING; CLINICAL FEATURE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FAT MASS; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; HUMAN; LEAN BODY WEIGHT; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUSCLE FUNCTION; MUSCLE MASS; NUTRITIONAL ASSESSMENT; NUTRITIONAL SUPPORT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SCORING SYSTEM; SKELETAL MUSCLE; TERTIARY CARE CENTER; VERY ELDERLY; WEIGHT REDUCTION; BLOOD; COLORECTAL TUMOR; COMPLICATION; LUNG TUMOR; MIDDLE AGED;

ANIMALIA;

ACTIVINS; ADULT; AGED; AGED, 80 AND OVER; BODY COMPOSITION; CACHEXIA; COLORECTAL NEOPLASMS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MYOSTATIN; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 84929359457     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-4318     Document Type: Article

References (43)

1. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12:489-495.
2. Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16:153-166.
3. Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15:2920-2926.
4. Parsons HA, Baracos VE, Dhillon N, Hong DS, Kurzrock R. Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One. 2012;7:e29330.
5. Xia Y, Schneyer AL. The biology of activin: recent advances in structure, regulation and function. J Endocrinol. 2009;202:1-12.
6. Michel U, Ebert S, Phillips D, Nau R. Serum concentrations of activin and follistatin are elevated and run in parallel in patients with septicemia. Eur J Endocrinol. 2003;148:559-564.
7. Hedger MP, de Kretser DM. The activins and their binding protein, follistatin-Diagnostic and therapeutic targets in inflammatory disease and fibrosis. Cytokine Growth Factor Rev. 2013;24:285-295.
8. de Kretser DM, Bensley JG, Pettila V, et al. Serum activin A and B levels predict outcome in patients with acute respiratory failure: a prospective cohort study. Crit Care. 2013;17:R263.
9. Harada K, Shintani Y, Sakamoto Y, Wakatsuki M, Shitsukawa K, Saito S. Serum immunoreactive activin A levels in normal subjects and patients with various diseases. J Clin Endocrinol Metab. 1996; 81:2125-2130.
10. Leto G, Incorvaia L, Badalamenti G, et al. Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis. 2006;23:117-122.
11. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387:83-90.
12. McPherron AC. Metabolic Functions of Myostatin and Gdf11. Immunol Endocr Metab Agents Med Chem. 2010;10:217-231.
13. Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142:531-543.
14. Chen JL, Walton KL, Winbanks CE, et al. Elevated expression of activins promotes muscle wasting and cachexia. FASEB J. 2014;28: 1711-1723.
15. Gilson H, Schakman O, Kalista S, Lause P, Tsuchida K, Thissen JP. Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin. Am J Physiol Endocrinol Metab. 2009;297:E157-164.
16. Durieux AC, Amirouche A, Banzet S, et al. Ectopic expression of myostatin induces atrophy of adult skeletal muscle by decreasing muscle gene expression. Endocrinology. 2007;148:3140-3147.
17. Zimmers TA, Davies MV, Koniaris LG, et al. Induction of cachexia in mice by systemically administered myostatin. Science. 2002;296: 1486-1488.
18. Busquets S, Toledo M, Orpí M, et al. Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J Cachexia Sarcopenia Muscle. 2012;3:37-43.
19. Gonzalez-Cadavid NF, Taylor WE, Yarasheski K, et al. Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci USA. 1998;95:14938-14943.
20. Yarasheski KE, Bhasin S, Sinha-Hikim I, Pak-Loduca J, Gonzalez-Cadavid NF. Serum myostatin-immunoreactive protein is increased in 60-92 year old women and men with muscle wasting. J Nutr Health Aging. 2002;6:343-348.
21. Breitbart A, Auger-Messier M, Molkentin JD, Heineke J. Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. Am J Physiol Heart Circ Physiol. 2011;300: H1973-1982.
22. Breitbart A, Scharf GM, Duncker D, et al. Highly specific detection of myostatin prodomain by an immunoradiometric sandwich assay in serum of healthy individuals and patients. PLoS One. 2013;8:e80454.
23. Lokireddy S, Wijesoma IW, Bonala S, et al. Myostatin is a novel tumoral factor that induces cancer cachexia. Biochem J. 2012;446: 23-36.
24. Wilson MM, Thomas DR, Rubenstein LZ, et al. Appetite assessment: simple appetite questionnaire predicts weight loss in community-dwelling adults and nursing home residents. Am J Clin Nutr. 2005;82:1074-1081.
25. Minton O, Stone P. A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann Oncol. 2009; 20:17-25.
26. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33:997-1006.
27. Aubrey J, Esfandiari N, Baracos VE, et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol (Oxf). 2014;210:489-497.
28. Gibson RS. Nutritional Assessment. New York, NY: Oxford University Press Inc.; 1993.
29. Piccoli A, Pillon L, Dumler F. Impedance vector distribution by sex, race, body mass index, and age in the United States: standard reference intervals as bivariate Z scores. Nutrition. 2002;18:153-167.
30. Goodpaster BH, Kelley DE, Thaete FL, He J, Ross R. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol. 2000;89:104-110.
31. Terpos E, Kastritis E, Christoulas D, et al. Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Ann Oncol. 2012;23:2681-2686.
32. Aversa Z, Bonetto A, Penna F, et al. Changes in myostatin signaling in non-weight-losing cancer patients. Ann Surg Oncol. 2012;19: 1350-1356.
33. Johns N, Hatakeyama S, Stephens NA, et al. Clinical classification of cancer cachexia: phenotypic correlates in human skeletal muscle. PLoS One. 2014;9:e83618.
34. Stephens NA, Skipworth RJ, Macdonald AJ, Greig CA, Ross JA, Fearon KC. Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J Cachexia Sarcopenia Muscle. 2011;2:111-117.
35. Antoun S, Lanoy E, Iacovelli R, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer. 2013;119:3377-3384.
36. Jones KL, Mansell A, Patella S, et al. Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc Natl Acad Sci U S A. 2007; 104:16239-16244.
37. Scott HR, McMillan DC, Crilly A, McArdle CS, Milroy R. The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br J Cancer. 1996;73:1560-1562.
38. Moses AG, Maingay J, Sangster K, Fearon KC, Ross JA. Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival. Oncol Rep. 2009;21:1091-1095.
39. Scheede-Bergdahl C, Watt HL, Trutschnigg B, et al. Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia? Clin Nutr. 2012;31:85-88.
40. Jatoi A, Ritter HL, Dueck A, et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer. 2010;68:234-239.
41. Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther. 2011;11:1663-1668.
42. Gaussin V, Depre C. Myostatin, the cardiac chalone of insulin-like growth factor-1. Cardiovasc Res. 2005;68:347-349.
43. Costelli P, Muscaritoli M, Bonetto A, et al. Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur J Clin Invest. 2008;38:531-538.